Abstract
In C. elegans, genetic and biochemical data indicate that the Cbl homolog Sli-1 attenuates Let-23 (EGFR) signaling. To investigate whether c-Cbl might have a role in mammalian growth factor-mediated mitogenic signaling, we microinjected NIH3T3 mouse fibroblasts with expression plasmids encoding wt and G306ECbl (a `loss of function' mutant identified in C. elegans). We observed inhibition of PDGF BB- and EGF-induced DNA synthesis by wt Cbl but not the mutant. Microinjection of two different affinity purified polyclonal antisera against Cbl boosted a suboptimal PDGF-stimulated mitogenic response. The inhibition of both PDGF BB- and EGF-induced DNA synthesis by wt Cbl was reversed by co-expression with Myc but not with Fos. DNA synthesis initiated by constitutively activated Src was also blocked by Cbl expression, but curiously by the G306E mutant as well. These data are all consistent with the proposition that Cbl negatively affects mitogenic signaling in mammalian fibroblasts.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout





Similar content being viewed by others
References
Barone MV and Courtneidge SA. . 1995 Nature 378: 509–512.
Blake TJ, Heath KG and Langdon WY. . 1993 EMBO J. 12: 2017–2026.
Blake TJ, Shapiro M, Morse III HC and Langdon WY. . 1991 Oncogene 6: 653–657.
Bonita DP, Miyake S, Lupher Jr ML, Langdon WY and Band H. . 1997 Mol. Cell Biol. 17: 4597–4610.
Caldenhoven E, van Dijk TB, Solari R, Armstrong J, Raaijmakers JAM, Lammers J-WJ, Koenderman L and de Groot RP. . 1996 J. Biol. Chem. 271: 13221–13227.
Fukazawa T, Reedquist KA, Trub T, Soltoff S, Panchamoorthy G, Druker B, Cantley L, Shoelson SE and Band H. . 1995 J. Biol. Chem. 270: 19141–19150.
Galisteo ML, Dikic I, Batzer AG, Langdon WY and Schlessinger J. . 1995 J. Biol. Chem. 270: 20242–20245.
Hime GR, Dhungat MP, Ng A and Bowtell DD. . 1997 Oncogene 14: 2709–2719.
Keane MM, Rivero-Lezcano OM, Mitchell JA, Robbins KC and Lipkowitz S. . 1995 Oncogene 10: 2367–2377.
Kypta RM, Goldberg Y, Ulug ET and Courtneidge SA. . 1990 Cell 62: 481–492.
Langdon WY, Hartley JW, Klinken SP, Ruscetti SK and Morse III HC. . 1989 Proc. Natl. Acad. Sci. USA 86: 1168–1172.
Lupher Jr ML, Reedquist KA, Miyake S, Langdon WY and Band H. . 1996 J. Biol. Chem. 271: 24063–24068.
Lupher Jr ML, Songyang Z, Shoelson SE, Cantley LC and Band H. . 1997 J. Biol. Chem. 272: 33140–33144.
Meisner H, Daga A, Buxton J, Fernandez B, Chawla A, Banerjee U and Czech MP. . 1997 Mol. Cell. Biol. 17: 2217–2225.
Meng W, Sawasdikosol S, Burakoff SJ and Eck MJ. . 1999 Nature 398: 84–90.
Miyake S, Lupher Jr ML, Andoniou CE, Lill NL, Ota S, Douillard P, Rao N and Band H. . 1997 Crit. Rev. Onco. 8: 189–218.
Miyake S, Lupher Jr ML, Druker B and Band H. . 1998 Proc. Natl. Acad. Sci. USA 95: 7927–7932.
Murphy MA, Schnall RG, Venter DJ, Barnett L, Bertoncello I, Thien CB, Langdon WY and Bowtell DDL. . 1998 Mol. Cell. Biol. 18: 4872–4882.
Ota Y and Samelson LE. . 1997 Science 276: 418–420.
Rellahan BL, Graham LJ, Stoica B, DeBell KE and Bonvini E. . 1997 J. Biol. Chem. 272: 30806–30811.
Richardson A and Parsons T. . 1996 Nature 380: 538–540.
Roche S, Alonso G, Kazlauskas A, Dixit VM, Courtneidge SA and Pandey A. . 1998 Curr. Biol. 8: 975–978.
Roche S, McGlade J, Jones M, Gish GD, Pawson T and Courtneidge SA. . 1996 EMBO J. 15: 4940–4948.
Smit L and Borst J. . 1997 Crit. Rev. Onco. 8: 359–379.
Superti-Furga G, Jonsson K and Courtneidge SA. . 1996 Nature Biotech. 14: 600–605.
Tanaka S, Amling M, Neff L, Peyman A, Uhlmann E, Levy JB and Baron R. . 1996 Nature 383: 528–531.
Thien CB and Langdon WY. . 1997 Oncogene 14: 2239–2249.
Tsygankov AY, Mahajan S, Fincke JE and Bolen JB. . 1996 J. Biol. Chem. 271: 27130–27137.
Ueno H, Sasaki K, Miyagawa K, Honda H, Mitani K, Yazaki Y and Hirai H. . 1997 J. Biol. Chem. 272: 8739–8743.
Yishimura T, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Hara T and Miyajima A. . 1995 EMBO J. 14: 2816–2826.
Yoon CH, Lee J, Jongeward GD and Sternberg PW. . 1995 Science 269: 1102–1105.
Acknowledgements
The authors wish to thank Dr Wallace Y Langdon for providing the wild-type and G306E mutant HA-tagged Cbl cDNAs.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Broome, M., Galisteo, M., Schlessinger, J. et al. The proto-oncogene c-Cbl is a negative regulator of DNA synthesis initiated by both receptor and cytoplasmic tyrosine kinases. Oncogene 18, 2908–2912 (1999). https://doi.org/10.1038/sj.onc.1202873
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.onc.1202873
Keywords
This article is cited by
-
The Src-like adaptor protein regulates PDGF-induced actin dorsal ruffles in a c-Cbl-dependent manner
Oncogene (2008)
-
The interplay between Src family kinases and receptor tyrosine kinases
Oncogene (2004)
-
TULA: an SH3- and UBA-containing protein that binds to c-Cbl and ubiquitin
Oncogene (2004)
-
Homologs of RUNX and CBFβ/PEBP2β in C. elegans
Oncogene (2004)
-
Beyond the RING: CBL proteins as multivalent adapters
Oncogene (2001)


